# US 2002/0119137 A1 · CGI-69 compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0119137 A1
- Document ID: US20020119137A1
- Status: Published application
- Kind: A1
- Application number: 09/888,358
- Filed: 2001-06-22
- Published: 2002-08-29
- Earliest claimed: 2000-06-22
- Inventors: Sean H. Adams; David Lewin; Xing Xian Yu
- Web page: https://patentgrep.com/patent/US20020119137A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- C07K 14/47: from mammals
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/5035: {on sub-cellular localization}
- G01N 33/5079: {Mitochondria}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C07K 2319/43: containing a FLAG-tag
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to the sequence SEQ ID NO:1, polynucleotides encoding these peptides, and antibodies to the polypeptides are useful in treating metabolic disorders or disorders associated with changes in adipose tissue physiological function or mass.

## Claims

### Claim 1

An isolated CGI-69 nucleic acid comprising:
(a) a nucleic acid sequence comprising at least 80% identity with SEQ ID NO:1, excluding the CGI-69 nucleic acid having the sequence of SEQ ID NO:2; or
(b) a complement of the nucleic acid sequence of (a).

### Claim 2 (depends on 1)

The isolated CGI-69 nucleic acid of claim 1 comprising:
(a) a nucleic acid sequence comprising at least 80% identity with a fragment of SEQ ID NO:1 consisting of nucleotide 14 to nucleotide 1093, excluding the CGI-69 nucleic acid having the sequence of SEQ ID NO:2 consisting of nucleotide 118 to nucleotide 1173; or
(b) a complement of the nucleic acid sequence of (a).

### Claim 3 (depends on 1)

The isolated CGI-69 nucleic acid of claim 1, wherein the nucleic acid sequence encodes a polypeptide comprising at least 80% identity with the polypeptide of SEQ ID NO:3, excluding the polypeptide of SEQ ID NO:4, wherein the polypeptide comprises at least one biological activity of the polypeptide of SEQ ID NO:3.

### Claim 4 (depends on 3)

The isolated CGI-69 nucleic acid of claim 3, wherein biological activity comprises mitochondrial localization.

### Claim 5 (depends on 1)

A vector comprising the isolated CGI-69 nucleic acid of claim 1.

### Claim 6 (depends on 1, 5)

The vector of claim 5, wherein the vector is an expression vector comprising the CGI-69 nucleic acid of claim 1 operably linked to a promoter.

### Claim 7 (depends on 6)

The vector of claim 6, wherein the promoter is recognized by a mammalian cell transformed with the vector.

### Claim 8 (depends on 5)

A host cell comprising the vector of claim 5.

### Claim 9 (depends on 8)

The host cell of claim 8, wherein the cell is a 293 cell.

### Claim 10

An isolated CGI-69 polypeptide comprising an amino acid sequence having at least 80% sequence identity to the sequence of SEQ ID NO:3, excluding the CGI-69 polypeptide having the sequence of SEQ ID NO:4.

### Claim 11 (depends on 10)

The isolated CGI-69 polypeptide of claim 10, wherein said polypeptide is a biologically active CGI-69 polypeptide.

### Claim 12 (depends on 10)

The isolated CGI-69 polypeptide of claim 10, wherein said amino acid sequence has at least 90% sequence identity to the sequence of SEQ ID NOS:3.

### Claim 13

A CGI-69 fusion protein comprising a polypeptide fused to the carboxy-terminus of a polypeptide comprising an amino acid sequence having at least 80% sequence identity to the sequence of SEQ ID NO:3.

### Claim 14 (depends on 13)

The CGI-69 fusion polypeptide of claim 13, wherein the fusion protein acts as an uncoupling protein.

### Claim 15 (depends on 14)

The CGI-69 fusion polypeptide of claim 14, wherein the polypeptide fused to the carboxy-terminus is negatively charged.

### Claim 16 (depends on 14)

The CGI-69 fusion polypeptide of claim 14, wherein the polypeptide fused to the carboxy-terminus comprises the sequence of SEQ ID NO:17.

### Claim 17 (depends on 10)

An antibody that specifically binds to the polypeptide of claim 10.

### Claim 18

A method of treating a metabolic disorder comprising modulating the activity of CGI-69.

### Claim 19 (depends on 18)

The method of claim 18, wherein said modulating activity of CGI-69 comprises decreasing the activity of CGI-69.

### Claim 20 (depends on 19)

The method of claim 19, wherein said decreasing activity comprises decreasing the expression of CGI-69.

### Claim 21 (depends on 20)

The method of claim 20, wherein said metabolic disorder is selected from the group consisting of cachexia, tumors, cancers, viral infections and bacterial infections.

### Claim 22 (depends on 18)

The method of claim 18, wherein said modulating activity of CGI-69 comprises increasing the activity of CGI-69.

### Claim 23 (depends on 22)

The method of claim 22, wherein said increasing activity comprises increasing the expression of CGI-69.

### Claim 24 (depends on 22)

The method of claim 22, wherein said metabolic disorder is selected from the group consisting of obesity, tumors, cancers, viral infections and bacterial infections.

### Claim 25

A method for determining whether a compound up-regulates or down-regulates expression of a CGI-69 gene in a cell, comprising:
(a) contacting the cell with said compound; and
(b) detecting expression of the gene.

### Claim 26 (depends on 25)

The method of claim 25, wherein mRNA encoding CGI-69 is detected.

### Claim 27 (depends on 25)

The method of claim 25, wherin a CGI-69 polypeptide is detected.

### Claim 28 (depends on 25)

The method of claim 25, wherin said composition is a cell.

### Claim 29

A transgenic non-human animal, having a disrupted CGI-69 gene.

### Claim 30 (depends on 29)

The transgenic non-human animal of claim 29, wherein the non-human animal is a mouse.

### Claim 31

A transgenic non-human animal, comprising a transgene having at least 80% sequence identity to the sequence of SEQ ID NO:1 or a complement of said sequence.

### Claim 32

A method of screening for a mutation in CGI-69 comprising comparing a nucleic acid sequence to the sequence of SEQ ID Nos:1 or 2.

### Claim 33

A method of measuring CGI-69 agonist or antagonist activity of a compound comprising:
(a) contacting a composition comprising CGI-69 activity with the compound; and
(b) determining a change in the CGI-69 activity.

### Claim 34 (depends on 33)

The method of claim 33, wherein the composition is a cell.
